JHS acquired the tech transfer for a COVID-19 liquid suspension vaccine product that was approved for use internationally, but not within the United States. This transfer was completed in less than half the time typically required. The challenge was developing a process to produce the vaccine in the US that did not compromise the sterility, or homogeneity, of the product.
Case Study: Zero Deviations on an Expedited Timeline
JHS successfully and rapidly produced a clinical trial batch and three process validation batches for a client working under US Operation Warp Speed producing COVID-19 vaccines.